<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: <z:chebi fb="0" ids="29007">Ceftriaxone</z:chebi> has been reported to reduce neuronal damage in <z:hpo ids='HP_0007354'>amyotrophic lateral sclerosis</z:hpo> and in an in-vitro model of neuronal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e> through increased expression and activity of the <z:chebi fb="6" ids="14321,29987">glutamate</z:chebi> transporter, GLT1 </plain></SENT>
<SENT sid="1" pm="."><plain>We tested the effects of <z:chebi fb="0" ids="29007">ceftriaxone</z:chebi> on mortality, neurological outcome, and <z:mpath ids='MPATH_124'>infarct</z:mpath> size in experimental <z:hpo ids='HP_0001297'>stroke</z:hpo> in rats and looked for underlying mechanisms </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Male normotensive Wistar rats received <z:chebi fb="0" ids="29007">ceftriaxone</z:chebi> (200 mg/kg intraperitoneal) as a single injection 90 min after middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (90 min with reperfusion) </plain></SENT>
<SENT sid="3" pm="."><plain>Forty-eight hours after middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp>, <z:mpath ids='MPATH_124'>infarct</z:mpath> size (MRI) and neurological deficits were estimated </plain></SENT>
<SENT sid="4" pm="."><plain>GLT1 expression was determined by real time RT-PCR, immunoblotting and promoter reporter assay, astrocyte GLT1 activity by measuring <z:chebi fb="6" ids="14321,29987">glutamate</z:chebi> uptake </plain></SENT>
<SENT sid="5" pm="."><plain><z:mp ids='MP_0001794'>Bacterial</z:mp> load in various organs was measured by real time RT-PCR, neurotrophins and IL-6 by immunoblotting </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: <z:chebi fb="0" ids="29007">Ceftriaxone</z:chebi> dramatically reduced early (24-h) mortality from 34.5% (vehicle treatment, n = 29) to 0% (P &lt; 0.01, n = 19) </plain></SENT>
<SENT sid="7" pm="."><plain>In a subgroup, followed up for 4 weeks, mortality persisted at 0% </plain></SENT>
<SENT sid="8" pm="."><plain><z:chebi fb="0" ids="29007">Ceftriaxone</z:chebi> strongly tended to reduce <z:mpath ids='MPATH_124'>infarct</z:mpath> size, it significantly improved neuronal survival within the penumbra, reduced neurological deficits (P &lt; 0.001) and led to an upregulation of neurotrophins (P &lt; 0.01) in the peri-<z:mpath ids='MPATH_124'>infarct</z:mpath> zone </plain></SENT>
<SENT sid="9" pm="."><plain><z:chebi fb="0" ids="29007">Ceftriaxone</z:chebi> did not increase GLT1 expression, but increased GLT1 activity (P &lt; 0.05) </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSION: <z:chebi fb="0" ids="29007">Ceftriaxone</z:chebi> causes a significant reduction in <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0001297'>stroke</z:hpo> mortality in a poststroke treatment regimen in animal studies </plain></SENT>
<SENT sid="11" pm="."><plain>Improved neurological performance and survival may be due to neuroprotection by activation of GLT1 and a stimulation of neurotrophins resulting in an increased number of surviving neurons in the penumbra </plain></SENT>
</text></document>